US$ 23.35
gip glp 1 agonists Understand GLP-1/GIP Dual Agonist Tirzepatide and Its Effect on Current Weight Loss Therapy New strategies for the treatment
Description
S., Anastasopoulou C

10.1038/379069a0

Even then, close gastroenterologist oversight and frequent monitoring are essential throughout treatment

Its less common among diabetic patients, who usually need lower doses of the same drug to achieve the desired result

Innovator Novo Nordisk launched its semaglutide brands Wegovy and Ozempic in India last year, racing to capture early market share before losing patent exclusivity on 20 March 2026
